文献速递肝病

非酒精性脂肪性肝炎治疗试验中组织学特征与诊断改善与纤维化改善相关:来自非酒精性脂肪性肝炎临床研究网络治疗试验的结果

Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
PubMed 文献 · Hepatology · 2019-03-07

该研究回顾性分析PIVENS和FLINT两项成人NASH治疗试验的基线及终末活检数据,探讨纤维化改善与特定组织学特征改善、NAS≥2改善、诊断分类及主要组织学结局的关联。结果显示纤维化改善与NASH消退及NAS≥2改善最强相关,且与脂肪变、气球样变、Mallory-Denk小体及门管区炎症改善相关,但与小叶内炎症无关。

要点

  • 纤维化改善与NASH消退最强相关:PIVENS OR 3.9,FLINT OR 8.0。
  • 纤维化改善与NAS≥2改善相关:PIVENS OR 2.4,FLINT OR 4.2。
  • 与纤维化改善相关的组织学特征包括脂肪变、气球样变、Mallory-Denk小体和门管区炎症,不包括小叶内炎症。

核心结论

  • 这些发现支持NASH组织学消退与纤维化改善之间存在强关联。

研究设计与样本

  • 回顾性分析PIVENS和FLINT两项成人NASH治疗试验的基线及终末活检数据,由NASH临床研究网络病理委员会收集。
  • PIVENS有221名受试者具备基线和96周活检,FLINT有200名受试者具备基线和72周活检。
  • 主要结局为纤维化从基线至治疗结束改善,定义为纤维化分期改善1分或以上。
  • 采用治疗组校正的单变量和多变量逻辑回归模型分析纤维化改善与其他组织学变量改善、脂肪性肝炎消退及NAS改善≥2的关联。

主要发现

  • 纤维化改善见于38%的PIVENS活检和29%的FLINT活检;两项研究中治疗组较安慰剂组更可能出现纤维化改善。
  • 控制治疗组后,纤维化改善与NASH消退最强相关:PIVENS OR 3.9(95%CI 2.0-7.6,P<0.001);FLINT OR 8.0(95%CI 3.1-20.9,P<0.001)。
  • 纤维化改善与NAS改善≥2相关:PIVENS OR 2.4(95%CI 1.3-4.3,P=0.003);FLINT OR 4.2(95%CI 2.1-8.3,P<0.001)。
  • 两项研究中与纤维化改善相关的组织学特征改善包括脂肪变、气球样变、Mallory-Denk小体和门管区炎症,但不包括小叶内炎症。

关键数值与推荐

  • 纤维化改善定义为纤维化分期改善1分或以上。
  • NAS改善≥2定义为非酒精性脂肪性肝病活动度评分改善2分或以上。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatocellular injury and inflammation are believed to be the primary drivers of fibrogenesis that ultimately lead to cirrhosis in patients with nonalcoholic steatohepatitis (NASH). This study sought associations between observed improvements in fibrosis with improvement in specific histologic features, nonalcoholic fatty liver disease activity score (NAS) ≥2, diagnostic category, and primary histologically based outcomes of two adult NASH treatment trials. The primary outcome for the study was fibrosis improvement from baseline to end of treatment, defined as a 1-point or more improvement in fibrosis stage. This is a retrospective analysis of biopsy data collected from the NASH Clinical Research Network Pathology Committee of Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with NASH Trial (PIVENS) and Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment Trial (FLINT) baseline and final biopsies. Treatment group-adjusted univariable and multivariable logistic regression models related improvement in fibrosis to improvements in other histologic variables, resolution of steatohepatitis, and improvement in the NAS ≥2. In PIVENS 221 subjects had baseline and 96-week biopsies, and in FLINT 200 subjects had baseline and 72-week biopsies. Improvement in fibrosis was found in 38% of PIVENS and 29% of FLINT biopsies; fibrosis improvement was more likely in treated than placebo subjects in both studies. Controlling for treatment group, fibrosis improvement was associated most strongly with resolution of NASH (PIVENS, odds ratio [OR], 3.9; 95% confidence interval [CI] 2.0-7.6; P < 0.001; FLINT, OR, 8.0; 95% CI 3.1-20.9; P < 0.001), and improved NAS by ≥2 (PIVENS, OR, 2.4; 95% CI 1.3-4.3; P = 0.003; FLINT, OR, 4.2; 95% CI 2.1-8.3; P < 0.001). Improvement in histologic features associated with improved fibrosis for both studies included steatosis, ballooning, Mallory-Denk bodies, and portal, but not lobular, inflammation. Conclusion: These findings support a strong link between histologic resolution of steatohepatitis with improvement in fibrosis in NASH.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Brunt EM, Kleiner DE, Wilson LA, et al. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Hepatology. 2019. PMID: 30549292. doi:10.1002/hep.30418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。